These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 9417540)
21. Two new fluoroquinolones. Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502 [No Abstract] [Full Text] [Related]
22. Grepafloxacin--a new fluoroquinolone. Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856 [No Abstract] [Full Text] [Related]
23. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections. Stein GE; Havlichek DH Pharmacotherapy; 1997; 17(6):1139-47. PubMed ID: 9399598 [TBL] [Abstract][Full Text] [Related]
24. New uses for new and old quinolones and the challenge of resistance. Hooper DC Clin Infect Dis; 2000 Feb; 30(2):243-54. PubMed ID: 10671323 [No Abstract] [Full Text] [Related]
25. Choosing the ideal antibiotic therapy and the role of the newer fluoroquinolones in respiratory tract infections. Owens RC Am J Manag Care; 2000 May; 6(8 Suppl):S442-7. PubMed ID: 10977484 [No Abstract] [Full Text] [Related]
26. Safety profile of sparfloxacin in the treatment of respiratory tract infections. Rubinstein E J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134 [TBL] [Abstract][Full Text] [Related]
27. New antibiotic approved for community-acquired infections. Nurse Pract; 1998 Jan; 23(1):94. PubMed ID: 9470200 [No Abstract] [Full Text] [Related]
28. [Efficiency of lomefloxacine in combined treatment of patients with multiresistant pulmonary tuberculosis complicated with nonspecific bronchopulmonary infection]. Mishin VIu; Vasil'eva IA; Martynova LP Probl Tuberk; 1999; (6):20-2. PubMed ID: 10715950 [No Abstract] [Full Text] [Related]
29. Efficacy of temafloxacin versus ciprofloxacin or amoxicillin for lower respiratory tract infections in smokers and the elderly. Davey PG Am J Med; 1991 Dec; 91(6A):101S-105S. PubMed ID: 1662877 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873 [TBL] [Abstract][Full Text] [Related]
31. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection. Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367 [No Abstract] [Full Text] [Related]
32. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats. Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic study of a new quinolone, DW-116. Lee DK Drugs; 1995; 49 Suppl 2():323-5. PubMed ID: 8549349 [No Abstract] [Full Text] [Related]
35. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. Ferguson J; Dawe R J Antimicrob Chemother; 1997 Dec; 40 Suppl A():93-8. PubMed ID: 9484878 [TBL] [Abstract][Full Text] [Related]
36. [Use of new quinolones in respiratory infections]. Sanz Moreno J; Jiménez Rodríguez A Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474 [No Abstract] [Full Text] [Related]
37. New generations of quinolones: with particular attention to levofloxacin. Ambrose PG; Owens RC; Quintiliani R; Nightingale CH Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076 [No Abstract] [Full Text] [Related]
38. [Respiratory tract infections--laboratory tests usually unnecessary. New quinolones recommended by professional groups considered]. Steiert P Fortschr Med; 1999 Feb; 117(6):41. PubMed ID: 10095302 [No Abstract] [Full Text] [Related]
39. Drug not considered a first-line agent. Lexchin J Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049 [No Abstract] [Full Text] [Related]
40. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections]. Iakovlev SV Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]